US-Listed In Vitro & In Vivo Diagnostic Substances — Total Assets Percentiles, FY 2023

Population: 19 US-listed companies (SIC 2835), fiscal year 2023; fiscal year ends 2023-06-30 to 2024-05-31.

Fiscal year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · latest

10th percentile	$5.9M
25th percentile	$12.5M
Median	$43.8M
75th percentile	$1.2B
90th percentile	$3.5B
Mean	$1.1B
Minimum	$2.3k
Maximum	$8.6B

Methodology & sources
Total Assets as filed, one fiscal year per company; percentiles computed in the database via percentile_cont, never by a model. Fiscal year 2023 = fiscal years ending 2023-06-01 to 2024-05-31 (majority-overlap rule; June-ending fiscal years count toward the ending calendar year).
Source: SEC EDGAR filings (public domain). Data: FACTANKER registry, precomputed 2026-09-03.

Evidence samples

Latest Total Assets percentiles (live) · All In Vitro & In Vivo Diagnostic Substances benchmarks · All industries

Cite as: FACTANKER, https://factanker.com/industries/sic-2835/total-assets/2023